End-of-day quote
Shanghai S.E.
06:00:00 2024-04-25 pm EDT
|
5-day change
|
1st Jan Change
|
11.46
CNY
|
+9.98%
|
|
+18.14%
|
-24.70%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
3,474
|
4,689
|
3,387
|
3,851
|
2,900
|
-
|
Enterprise Value (EV)
1 |
3,474
|
4,689
|
3,387
|
3,851
|
2,900
|
2,900
|
P/E ratio
|
22.9
x
|
34.4
x
|
49.7
x
|
47.6
x
|
21
x
|
18.2
x
|
Yield
|
-
|
0.86%
|
0.75%
|
0.66%
|
1.66%
|
2.01%
|
Capitalization / Revenue
|
3.62
x
|
4.07
x
|
2.91
x
|
3.21
x
|
2.01
x
|
1.78
x
|
EV / Revenue
|
3.62
x
|
4.07
x
|
2.91
x
|
3.21
x
|
2.01
x
|
1.78
x
|
EV / EBITDA
|
-
|
-
|
-
|
19.5
x
|
8.33
x
|
6.65
x
|
EV / FCF
|
-
|
-11,607,096
x
|
-13,735,839
x
|
-
|
-
|
-
|
FCF Yield
|
-
|
-0%
|
-0%
|
-
|
-
|
-
|
Price to Book
|
-
|
2.92
x
|
2.06
x
|
2.25
x
|
1.61
x
|
1.51
x
|
Nbr of stocks (in thousands)
|
216,534
|
252,085
|
252,412
|
253,029
|
253,029
|
-
|
Reference price
2 |
16.04
|
18.60
|
13.42
|
15.22
|
11.46
|
11.46
|
Announcement Date
|
4/20/21
|
4/19/22
|
4/26/23
|
4/25/24
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
960.2
|
1,151
|
1,163
|
1,199
|
1,440
|
1,626
|
EBITDA
1 |
-
|
-
|
-
|
197.2
|
348
|
436
|
EBIT
1 |
-
|
170.9
|
102.9
|
122.9
|
192.5
|
225.5
|
Operating Margin
|
-
|
14.85%
|
8.85%
|
10.25%
|
13.37%
|
13.86%
|
Earnings before Tax (EBT)
1 |
-
|
171.4
|
102.2
|
122.5
|
192.5
|
225
|
Net income
1 |
-
|
132.6
|
69.84
|
80.71
|
137.5
|
160
|
Net margin
|
-
|
11.52%
|
6%
|
6.73%
|
9.55%
|
9.84%
|
EPS
2 |
0.7000
|
0.5400
|
0.2700
|
0.3200
|
0.5450
|
0.6300
|
Free Cash Flow
|
-
|
-404
|
-246.6
|
-
|
-
|
-
|
FCF margin
|
-
|
-35.1%
|
-21.2%
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
0.1600
|
0.1000
|
0.1000
|
0.1900
|
0.2300
|
Announcement Date
|
4/20/21
|
4/19/22
|
4/26/23
|
4/25/24
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-404
|
-247
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
9.42%
|
4.3%
|
4.82%
|
7.37%
|
8.04%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
4.03%
|
4.44%
|
Assets
1 |
-
|
-
|
-
|
-
|
3,412
|
3,604
|
Book Value Per Share
2 |
-
|
6.370
|
6.520
|
6.750
|
7.140
|
7.570
|
Cash Flow per Share
2 |
-
|
-
|
0.3800
|
0.6100
|
0.9700
|
1.150
|
Capex
1 |
-
|
493
|
342
|
215
|
224
|
247
|
Capex / Sales
|
-
|
42.88%
|
29.4%
|
17.91%
|
15.52%
|
15.16%
|
Announcement Date
|
4/20/21
|
4/19/22
|
4/26/23
|
4/25/24
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -24.70% | 400M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|